Table 2. Individual Study Characteristics.
TAVI- Transcatheter aortic valve implantation, PH- Pulmonary Hypertension, AS- Aortic stenosis, NYHA- New York Heart Association, AVA-Aortic valve area, RHC- Right Heart Catheterization, RCT- Randomized Controlled Trial, Ipc-PH: Isolated post-capillary Pulmonary Hypertension, Cpc-PH: Combined pre and post-capillary Pulmonary Hypertension, Pc-PH: Precapillary Pulmonary Hypertension.
| Study Name | Year | Type of Study | Population | Country | Number of Patients | Percentage of population with PH | Comparison group | Age (years) | Proportion of Male (%) |
| Sinning et al. [16] | 2014 | Prospective Study | Patient with severe AS undergoing TAVI | Germany, United Kingdoms | 353 | 71% | No PH vs mild to moderate PH vs Severe PH | 81.1±6.6 | 52.6 |
| Lindman et al. [29] | 2015 | RCT with continued access registry | Patients were symptomatic (NYHA) functional class ≥2 and had severe (AS) with an (AVA) <0.8 cm2 (or indexed AVA <0.5 cm2/m2) and either resting or inducible mean gradient >40 mm Hg or peak jet velocity >4 m/s | USA | 2180 | 64% | No PH vs. Mild vs. Severe | 85±7 vs. 84±7 vs. 83±8 | 47.00% |
| O'Sullivan et al. [1] | 2015 | Prospective cohort | Severe symptomatic AS (index AVA<0.6 cm2/m2) undergoing a preprocedural RHC were considered for inclusion | Switzerland | 433 | 75% | No PH vs. PH and PH was dichotomized into Post Cap PH vs. Pre-Cap PH. Post Cap PH was again dichotomized into Isolated Post Cap PH and Combined PH | 82.4±5.3 | 44% |
| Barbash et al. [21] | 2015 | Observational | Symptomatic severe AS who underwent TAVI from 2007 to 2013 | USA | 415 | 59% | No/mild PH vs Moderate/severe PH | 84±8 | 47% |
| Testa et al. [24] | 2016 | Observational | Patient with Severe AS undergoing TAVI | Italy | 999 | 22% | No PH vs. Moderate PH vs. Severe Ph | Group 1- 82±5 Group 2 - 81±7 Group 3 - 78±6 | 46% |
| Nijenhuis et al. [25] | 2016 | Observational | Patient undergoing TAVI | Netherland | 687 | 59% | Low vs. Moderate vs. High probability of PH based on TRV on TTE | 80.8±6.8 | 43.70% |
| Kleczynski et al. [26] | 2017 | Observational | Severe AS with Contraindication to SAVR and undergoing TAVI | Poland | 148 | 43.9% | PH vs no PH | 81.2±5.9 | 37.80% |
| Masri et al. [17] | 2018 | Retrospective | Patient undergoing TAVI | United States | 407 | 67 | No PH vs. Persistent PH Post TAVI | 82±7 | 50 |
| Schewel et al. [18] | 2019 | Retrospective | Symptomatic severe AS undergoing TAVI | Germany | 1400 | 53 | 81.5±6.8 | 46.3 | |
| Alushi et al. [15] | 2019 | Retrospective | Patient with Severe AS undergoing TAVI | Germany, Switzerland, and the United Kingdom. Multicenter | 617 | 49 | Reversible PH post-TAVI vs. Residual PH post-TAVI | 81±7 | 49 |
| Keymel et al. [27] | 2019 | Retrospective | Patient with Severe AS undergoing TAVI | Germany | 125 | 58.4 | AS with PH and AS without PH | AS + PH vs. AS − PH: 78.9 6.3 vs. 78.0 5.9 | 67% |
| Sultan et al. [12] | 2020 | Retrospective | Patient undergoing TAVI | United States | 614 | 67.3 | Pc-PH, Ipc-PH vs. No PH, Cpc-PH vs. no PH | 82.4±7.8 | 51% |
| Mujeeb et al. [28] | 2021 | Retrospective | National Database of patients who underwent TAVI | United States | 13085 | 12.7 | PH with AS vs. No PH with AS | 80.9±8.5 | 48% |
| Tang et al. [30] | 2016 | Meta-analysis | TAVI patient diagnosed with PH | China | 9204 | NA | PH with AS vs. no PH with AS | - | - |
| Kokkinidis et al. [11] | 2018 | Meta-analysis | Severe AS undergoing TAVI | United States | 17634 | - | - | - | - |